Evidence map›Paper›PMID 42495390›Full record

ArticleACS omega2026

Targeted Design of Novel Antimicrobial Peptides against

Yuping Wei, Kun Liu, Man Zhang, Yi Liu, Ruirui Sun, Yulin Yang, Like Zhang, Qiuhong Niu, Quanxiao Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuping WeiCollege of Life Sciences, Nanyang Normal University, Nanyang, Henan 473061, China.ORCID https://orcid.org/0000-0002-0069-3906
Kun LiuCollege of Life Sciences, Nanyang Normal University, Nanyang, Henan 473061, China.
Man ZhangDepartment of Oncology, Nanyang the First People's Hospital, Nanyang, Henan 473002, China.
Yi LiuCollege of Life Sciences, Nanyang Normal University, Nanyang, Henan 473061, China.
Ruirui SunCollege of Life Sciences, Nanyang Normal University, Nanyang, Henan 473061, China.
Yulin YangCollege of Life Sciences, Nanyang Normal University, Nanyang, Henan 473061, China.
Like ZhangDepartment of Oncology, Nanyang the First People's Hospital, Nanyang, Henan 473002, China.
Qiuhong NiuCollege of Life Sciences, Nanyang Normal University, Nanyang, Henan 473061, China.ORCID https://orcid.org/0000-0003-1695-7117
Quanxiao XuDepartment of Oncology, Nanyang the First People's Hospital, Nanyang, Henan 473002, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to the rising worldwide concern of antibiotic resistance, the creation of new antimicrobial agents has become an essential necessity. Novel antimicrobial peptides (AMPs), celebrated for their extensive efficacy and minimal likelihood of resistance development, are considered among the most promising treatment options. This paper introduced the rational design and synthesis of a new antimicrobial peptide, RK7 (RKKYWLL), which targeted the biophysical differences between human and

Identifiers

PMID42495390
PMCPMC13393366

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.